{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:51:01Z","timestamp":1783749061657,"version":"3.55.0"},"reference-count":60,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1254\/jphs.10099fp","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T07:53:50Z","timestamp":1287042830000},"page":"320-331","source":"Crossref","is-referenced-by-count":18,"title":["Antipsychotic Potential of Quinazoline ErbB1 Inhibitors in a Schizophrenia Model Established With Neonatal Hippocampal Lesioning"],"prefix":"10.1254","volume":"114","author":[{"given":"Makoto","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Iwakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyoshi","family":"Eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia – support for the developmental model. Mol Psychiatry. 2000;5:594–603.","DOI":"10.1038\/sj.mp.4000730"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Lang UE, Jockers-Scherübl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J Neural Transm. 2004;111:387–411.","DOI":"10.1007\/s00702-003-0100-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221–232.","DOI":"10.1038\/nrn2054"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull. 2009;35:959–972.","DOI":"10.1093\/schbul\/sbn022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry. 2002;7:673–682.","DOI":"10.1038\/sj.mp.4001081"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, et al. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res. 2008;101:58–66.","DOI":"10.1016\/j.schres.2008.01.017"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.9.4813"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–452.","DOI":"10.1038\/nrn2392"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21635"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001138"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Mizuno M, Malta RS Jr, Nagano T, Nawa H. Conditioned place preference and locomotor sensitization after repeated administration of cocaine or methamphetamine in rats treated with epidermal growth factor during the neonatal period. Ann N Y Acad Sci. 2004;1025:612–618.","DOI":"10.1196\/annals.1316.076"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Tohmi M, Tsuda N, Mizuno M, Takei N, Frankland PW, Nawa H. Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behav Genet. 2005;35:615–629.","DOI":"10.1007\/s10519-005-5357-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sotoyama H, Namba H, Takei N, Nawa H. Neonatal exposure to epidermal growth factor induces dopamine D2-like receptor supersensitivity in adult sensorimotor gating. Psychopharmacology (Berl). 2007;191:783–792.","DOI":"10.1007\/s00213-006-0595-9"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2008.01.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Mizuno M, Kawamura H, Takei N, Nawa H. The anthraquinone derivative Emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J Neural Transm. 2008;115:521–530.","DOI":"10.1007\/s00702-007-0867-5"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00137-8"},{"key":"17","unstructured":"17 Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci. 2004;29:282–286."},{"issue":"1","key":"18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/npp.1993.44","volume":"9","year":"1993","ISSN":"https:\/\/id.crossref.org\/issn\/0893-133X","issn-type":"print"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050349"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Al-Amin HA, Shannon Weickert C, Weinberger DR, Lipska BK. Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol Psychiatry. 2001;49:528–539.","DOI":"10.1016\/S0006-3223(00)00968-9"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246438"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246439"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Chambers RA, Moore J, McEvoy JP, Levin ED. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology. 2001;15:587–594.","DOI":"10.1016\/S0893-133X(96)00132-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Grecksch G, Bernstein GH, Becker A, Hollt V, Bogerts B. Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology. 1999;20:525–532.","DOI":"10.1016\/S0893-133X(98)00081-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B. Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology. 2002;27:47–54.","DOI":"10.1016\/S0893-133X(02)00282-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Levin ED, Christopher NC. Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:223–229.","DOI":"10.1016\/j.pnpbp.2005.10.018"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Richtand NM, Taylor B, Welge JA, Ahlbrand R, Ostrander MM, Burr J, et al. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology. 2006;31:77–89.","DOI":"10.1038\/sj.npp.1300791"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Lipska BK, Lerman DN, Khaing ZZ, Weickert CS, Weinberger DR. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur J Neurosci. 2003;18:391–402.","DOI":"10.1046\/j.1460-9568.2003.02738.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Nadri C, Lipska BK, Kozlovsky N, Weinberger DR, Belmaker RH, Agam G. Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. Dev Brain Res. 2003;141:33–37.","DOI":"10.1016\/S0165-3806(02)00639-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Endo K, Hori T, Abe S, Asada T. Alterations in GABA(A) receptor expression in neonatal ventral hippocampal lesioned rats: comparison of prepubertal and postpubertal periods. Synapse. 2007;61:357–366.","DOI":"10.1002\/syn.20393"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res. 2009;204:295–305.","DOI":"10.1016\/j.bbr.2008.11.039"},{"key":"32","unstructured":"32 Fry DW. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des. 2000;15:3–16."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003;4:397–406.","DOI":"10.1016\/S1470-2045(03)01137-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Mizuno M, Sotoyama H, Narita E, Kawamura H, Namba H, Zheng Y, et al. A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. J Neurosci. 2007;27:10116–10127.","DOI":"10.1523\/JNEUROSCI.2368-07.2007"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1021\/bc0602937"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol. 2000;11:185–204.","DOI":"10.1097\/00008877-200006000-00002"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100799"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Takahashi K, et al. Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen. Neuropsychopharmacology. 2008;33:3164–3175.","DOI":"10.1038\/npp.2008.41"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Zhang WN, Murphy CA, Feldon J. Behavioural and cardiovascular responses during latent inhibition of conditioned fear: measurement by telemetry and conditioned freezing. Behav Brain Res. 2004;154:199–209.","DOI":"10.1016\/j.bbr.2004.02.016"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0329"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Association of EGF polymorphism with schizophrenia in Finnish men. Neuroreport. 2004;15:1215–1218.","DOI":"10.1097\/00001756-200405190-00027"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. Ann Med. 2004;36:62–71.","DOI":"10.1080\/07853890310017585"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.11.002"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res. 2006;56:2–13.","DOI":"10.1016\/j.neures.2006.06.002"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–452.","DOI":"10.1038\/nrn2392"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.038"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.057"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1021\/jm990345w"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1021\/jm010428o"},{"issue":"24","key":"50","first-page":"8887","volume":"61","author":"MOULDER S L","year":"2001","ISSN":"https:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"key":"51","unstructured":"51 Kim TE, Murren JR. Erlotinib OSI\/Roche\/Genentech. Curr Opin Investig Drugs. 2002;3:1385–1395."},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1021\/jm9503613"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.4302"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Rueter LE, Ballard ME, Gallagher KB, Basso AM, Curzon P, Kohlhaas KL. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl). 2004;176:312–319.","DOI":"10.1007\/s00213-004-1897-4"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Le Pen G, Moreau JL. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology. 2002;27:1–11.","DOI":"10.1016\/S0893-133X(01)00383-9"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Weiner I, Feldon J. The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action. Psychopharmacology (Berl). 1994;116:379–381.","DOI":"10.1007\/BF02245344"},{"issue":"1","key":"57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","year":"1989","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303364200"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403899200"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803955106"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T18:56:41Z","timestamp":1740596201000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/114\/3\/114_10099FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10099fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}